Transplantation: Personalizing induction therapy in kidney transplantation

Nat Rev Nephrol. 2009 Nov;5(11):619-20. doi: 10.1038/nrneph.2009.164.

Abstract

Induction therapy with rabbit anti-thymocyte globulin is preferable to induction with daclizumab in renal transplant recipients at high immunological risk. These findings provide additional support to the idea that personalized immunosuppressive regimens should be developed in renal transplant recipients.

Publication types

  • News

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antilymphocyte Serum / therapeutic use*
  • Daclizumab
  • Graft Rejection / drug therapy*
  • Graft Rejection / epidemiology
  • Humans
  • Immunoglobulin G / therapeutic use
  • Immunosuppressive Agents / therapeutic use*
  • Incidence
  • Kidney Transplantation*
  • Precision Medicine / methods*
  • Risk Factors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antilymphocyte Serum
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Daclizumab